Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increased incidence of coagulation disorders
3.2.1.2 Growing demand for plasma-related therapies
3.2.1.3 Technological innovations
3.2.1.4 Advancements in research and development
3.2.2 Industry pitfalls & challenges
3.2.2.1 Intense competition from alternatives
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Reimbursement scenario
3.7 Pricing analysis
3.7.1 By region
3.7.2 By product
3.8 Future market trends
3.9 Patent analysis
3.10 Profit margin analysis
3.11 Pipeline analysis
3.12 Clinical trial landscape
3.13 Gap analysis
3.14 Porter’s analysis
3.15 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 4-factor PCC
5.3 3-factor PCC
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Acquired coagulation factor deficiency
6.3 Congenital coagulation factor deficiency
6.4 Other applications
Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 CSL
9.2 Baxter
9.3 Emergent BioSolutions
9.4 Grifols Biologicals
9.5 Intas Pharmaceuticals
9.6 Kedrion Biopharma
9.7 LFB Group
9.8 Octapharma
9.9 Pfizer
9.10 Prothya Biosolutions
9.11 Takeda Pharmaceuticals
